Literature DB >> 33990912

Comparative analysis of type 2 diabetes-associated gut microbiota between Han and Mongolian people.

Shu-Chun Li1, Yao Xiao1, Ri-Tu Wu1, Dan Xie1, Huan-Hu Zhao1, Gang-Yi Shen2, En-Qi Wu3.   

Abstract

Due to the different rates of diabetes in different ethnic groups and the structural differences in intestinal microbiota, this study evaluated the changes in diabetes-related intestinal microbiota in two ethnic groups. Fifty-six stool samples were collected from subjects from the Han and Mongolian ethnic groups in China, including participants without diabetes (non-diabetic, ND) and with type 2 diabetes (T2D). The 16S rDNA gene V3 + V4 area was extracted from microbiota, amplified by PCR, and used to perform high-throughput sequencing and screen differential microbiota associated with ethnicity. The results showed that there were 44 T2D-related bacterial markers in the Han subjects, of which Flavonifractor, Alistipes, Prevotella, Oscillibacter, Clostridium XlVa, and Lachnospiracea_incertae_sedis were most closely related to diabetes. There were 20 T2D-related bacterial markers in the Mongolian subjects, of which Fastidiosipila and Barnesiella were most closely related to diabetes. The common markers of T2D bacteria in the two ethnic groups were Papillibacter and Bifidobacterium. There were 17 metabolic pathways with significant differences between the ND and T2D groups in the Han group, and 29 metabolic pathways in the Mongolian group. The glutamatergic metabolic pathway was the only common metabolic pathway in two ethnic groups. The composition and function of diabetes-related bacteria were significantly different among the different ethnic groups, which suggested that the influence of ethnic differences should be fully considered when studying the association between diabetes and bacteria. In addition, the common bacterial markers found in diabetic patients of different ethnic groups in this study can be used as potential targets to study the pathogenesis and treatment of diabetes.

Entities:  

Keywords:  16S rDNA; Han; Mongolian; differential microbiota; ethnic group; type 2 diabetes

Year:  2021        PMID: 33990912     DOI: 10.1007/s12275-021-0454-8

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  4 in total

1.  [Gut Microbiome Differences between Gastrointestinal Cancer Patients and Healthy People].

Authors:  Ning Ning Li; Chun Mei Bai; Lin Zhao; Yu Ping Ge
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2019-10-30

Review 2.  From the intestinal flora to the microbiome.

Authors:  Juan José Sebastián Domingo; Clara Sánchez Sánchez
Journal:  Rev Esp Enferm Dig       Date:  2018-01       Impact factor: 2.086

3.  Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study.

Authors:  Jessica E Harbison; Alexandra J Roth-Schulze; Lynne C Giles; Cuong D Tran; Katrina M Ngui; Megan A Penno; Rebecca L Thomson; John M Wentworth; Peter G Colman; Maria E Craig; Grant Morahan; Anthony T Papenfuss; Simon C Barry; Leonard C Harrison; Jennifer J Couper
Journal:  Pediatr Diabetes       Date:  2019-05-20       Impact factor: 4.866

Review 4.  A Reasonable Diet Promotes Balance of Intestinal Microbiota: Prevention of Precolorectal Cancer.

Authors:  Pan Huang; Yi Liu
Journal:  Biomed Res Int       Date:  2019-07-25       Impact factor: 3.411

  4 in total
  2 in total

1.  The Microbiota Profile Analysis of Combined Periodontal-Endodontic Lesions Using 16S rRNA Next-Generation Sequencing.

Authors:  Ping Sun; Zhiyong Guo; Daiping Guo; Jian Wang; Tingting Wu; Tingjun Li; Jiannan Liu; Xinhua Liu
Journal:  J Immunol Res       Date:  2021-11-16       Impact factor: 4.818

Review 2.  Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites.

Authors:  Dongmei Wang; Jieying Liu; Liyuan Zhou; Qian Zhang; Ming Li; Xinhua Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-13       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.